The content on this site is intended for healthcare professionals only
Dr Anne Chiang talks to ecancer about phase 1 findings for ABBV-706, a first-in-class antibody-drug conjugate (ADC) targeting SEZ6, a protein highly expressed in small cell lung cancer (SCLC).
ABBV-706 delivers a potent topoisomerase 1 inhibitor payload directly to tumour cells.
In patients with relapsed/refractory SCLC treated at the recommended phase 3 dose, ABBV-706 achieved an objective response rate of 56% and median overall survival of 12.4 months. In the subgroup receiving second-line treatment, the response rate reached 82%, with median overall survival of 14.3 months.
Dr Chiang explores biomarker findings, including early declines in circulating tumour DNA and proGRP, and preclinical evidence supporting selective tumour targeting.
These results highlight ABBV-706’s future potential as a new treatment approach for patients with limited options, warranting further clinical investigation.
Subcutaneous tarlatamab shows encouraging efficacy in previously treated extensive-stage SCLC
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC
Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma
Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma
Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification
The potential of T-cell engagers in SCLC treatment
ASCO 2025: Latest in EGFR positive NSCLC
Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC
